About Heparan-sulfate 6-O-sulfotransferase 1
Heparan-sulfate 6-O-sulfotransferase 1 (HS6ST1) is a protein
from Homo sapiens identified by UniProt accession
O60243, 411 residues long.
MolForge cross-references it against 0 known binders and
73 disease associations.
Target properties
| Protein name | Heparan-sulfate 6-O-sulfotransferase 1 |
| UniProt accession | O60243 |
| Gene | HS6ST1 |
| Organism | Homo sapiens |
| Length | 411 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (73)
Diseases linked to this target (Open Targets).
- Kallmann syndrome · score 0.44
- hypogonadotropic hypogonadism · score 0.40
- lymphocyte count · score 0.36
- body height · score 0.31
- heel bone mineral density · score 0.30
- blood protein measurement · score 0.29
- lymphocyte:monocyte ratio · score 0.26
- lymphocyte percentage of leukocytes · score 0.25
- brain measurement · score 0.20
- age-related macular degeneration · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60243-F1 | alphafold | PREDICTED | 86.64 | — |
Amino-acid sequence (411 residues)
MRRRRAGGRT MVERASKFVL VVAGSVCFML ILYQYAGPGL SLGAPGGRAP PDDLDLFPTP DPHYEKKYYF PVRELERSLR FDMKGDDVIV FLHIQKTGGT TFGRHLVQNV RLEVPCDCRP GQKKCTCYRP NRRETWLFSR FSTGWSCGLH ADWTELTNCV PGVLDRRDSA ALRTPRKFYY ITLLRDPVSR YLSEWRHVQR GATWKTSLHM CDGRTPTPEE LPPCYEGTDW SGCTLQEFMD CPYNLANNRQ VRMLADLSLV GCYNLSFIPE GKRAQLLLES AKKNLRGMAF FGLTEFQRKT QYLFERTFNL KFIRPFMQYN STRAGGVEVD EDTIRRIEEL NDLDMQLYDY AKDLFQQRYQ YKRQLERREQ RLRSREERLL HRAKEALPRE DADEPGRVPT EDYMSHIIEK W
Explore Heparan-sulfate 6-O-sulfotransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets